Luis Quintero, MD
Endocrinology, Diabetes & Metabolism · Coral Gables, FLNPI 1710073648
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 394 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.
Across 394 payments — averaging $26.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Insulet Corporation$1K
- Sanofi-aventis U.S. LLC$982
- Novo Nordisk$857
- Dexcom, Inc.$851
- Lilly USA, LLC$753
- plus $5K from 34 others
Across 88 payments — averaging $4474.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$165K
- Pfizer$110K
- AbbVie$51K
- Boehringer Ingelheim International GmbH$34K
- Chiasma, Inc.$25K
- AstraZeneca$8K
- plus $2K from 1 others
What the payments were for
- Speaking & faculty fees$4755%
- Travel & lodging$3453%
- Food & beverage$9,71592%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 49 | $1,253 |
| Insulet Corporation | 47 | $1,046 |
| Sanofi-aventis U.S. LLC | 18 | $982 |
| Novo Nordisk | 41 | $857 |
| Dexcom, Inc. | 41 | $851 |
| Lilly USA, LLC | 37 | $753 |
| Corcept Therapeutics | 30 | $742 |
| Pfizer | 3 | $644 |
| AstraZeneca(2 entities) | 19 | $492 |
| Bayer | 17 | $403 |
| Boehringer Ingelheim | 18 | $357 |
| Xeris Pharmaceuticals, Inc. | 10 | $213 |
| Acadia Pharmaceuticals Inc | 2 | $191 |
| Ascensia Diabetes Care US Inc. | 1 | $161 |
| Shire North American Group Inc | 3 | $153 |
| Amgen(2 entities) | 7 | $147 |
| AbbVie | 9 | $146 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $124 |
| Eisai Inc. | 2 | $116 |
| Neurocrine Biosciences, Inc. | 1 | $104 |
| Cequr Corporation | 3 | $96 |
| Abbott | 5 | $87 |
| Madrigal Pharmaceuticals | 2 | $77 |
| Esperion Therapeutics, Inc. | 3 | $65 |
| Merck | 5 | $60 |
| Radius Health, Inc. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $41 |
| Sequel Med Tech, LLC | 2 | $40 |
| ZOLL Medical Corporation | 1 | $35 |
| Lifescan, Inc. | 1 | $34 |
| Valeritas, Inc. | 2 | $30 |
| Novartis | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Covidien LP | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Abiomed | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$475
- DEXCOM G6 TRANSMITTER$217
- EVERSENSE E3 SMART TRANSMITTER KIT$161
- Omnipod$144
- Minimed Paradigm Revel$126
- Tresiba$125
- FARXIGA$125
- TOUJEO$124
- CAPLYTA$124
- Ozempic$120
- RYBELSUS$119
- Korlym$115
- INGREZZA$104
- Dayvigo$100
How this compares
$10,549 in reported general payments places this provider in the 70th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 500 | $588,907 |
| TrulicityDulaglutide | 151 | $231,442 |
| MounjaroTirzepatide | 142 | $157,690 |
| JardianceEmpagliflozin | 120 | $143,406 |
| FarxigaDapagliflozin Propanediol | 116 | $121,169 |
| JanuviaSitagliptin Phosphate | 87 | $98,120 |
| TradjentaLinagliptin | 48 | $65,916 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $59,764 |
| GlyxambiEmpagliflozin/Linagliptin | 58 | $53,071 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $47,205 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $34,676 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $31,502 |
| Humalog Kwikpen U-200Insulin Lispro | 34 | $31,319 |
| Humalog Kwikpen U-100Insulin Lispro | 102 | $30,438 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $26,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $857 | $594,547516 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humalog Mix 75-25 | $753 | $417,898388 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr, Synjardy | $357 | $336,447314 claims |
| AstraZenecaFarxiga | $492 | $121,169116 claims |
| MerckJanuvia, Janumet | $60 | $112,668108 claims |
| PfizerEliquis | $644 | $18,64618 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $982 | $17,98115 claims |
| AbbVieSynthroid | $146 | $10,966114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Coral Gables
- Misha DenhamCoral Gables$673K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.